首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial.
【24h】

One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial.

机译:经皮下旋旋斑块切除术抽吸下道周围动脉闭塞性疾病的一年结果:多中心途径PVD试验。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To report a safety and efficacy study of a novel rotational atherectomy system with aspiration capabilities for the treatment of infrainguinal arterial lesions. METHODS: From February 2006 to January 2007, 172 patients (88 women; mean age 72 years, range 51-93; 47% diabetics) with Rutherford class 1-5 lower limb ischemia were enrolled at 9 study sites. Inclusion criteria were atherosclerotic stenoses >70% and up to 10 cm long in the femoropopliteal segment or up to 3 cm long in the infrapopliteal vessels (reference vessel diameter 3.0-5.0 mm). In the study, 210 lesions (mean length 2.7 cm) were treated with the Pathway PV System, including total occlusions (31%), lesions with a moderate to high calcium score (51%), and post-angioplasty (non-stent) restenotic lesions (15%). The primary study endpoint was the 30-day major adverse event (MAE) rate. RESULTS: Device success was 99% (208/210 lesions). MAE at 30 days was 1% (2 preplanned amputations). Clinically driven target lesion revascularization rates at 6 and 12 months were 15% (25/172) and 26% (42/162), respectively. The 1-year restenosis rate was 38.2% based on duplex imaging. The ankle-brachial index increased significantly from 0.59+/-0.21 at baseline to 0.82+/-0.27 (p<0.05) at 12 months. Mean Rutherford class improved from 3.0+/-0.9 at baseline to 1.5+/-1.3 at 1 year (p<0.05). CONCLUSION: The use of the Pathway PV System in atherosclerotic lesions appears to be safe and effective in improving stenosis severity, even in the presence of challenging lesion conditions. Vessel patency following intervention appears to be good up to 12 months, and these results translate into clinical benefit.
机译:目的:报告一种新型的具有抽吸功能的旋转旋磨术系统的安全性和有效性研究,该系统可治疗下鞘膜动脉病变。方法:从2006年2月至2007年1月,在9个研究地点招募了172例Rutherford 1-5级下肢缺血的患者(88名女性;平均年龄72岁,范围51-93; 47%的糖尿病患者)。纳入标准为动脉pop狭窄> 70%,股pop段最长10 ​​cm,或fra下血管长3 cm(参考血管直径3.0-5.0 mm)。在该研究中,使用Pathway PV System治疗了210个病变(平均长度2.7 cm),包括总闭塞(31%),中度至高钙评分的病变(51%)和血管成形术后(非支架)再狭窄病变(15%)。主要研究终点为30天主要不良事件(MAE)发生率。结果:设备成功率为99%(208/210个病变)。 30天时的MAE为1%(2次计划的截肢)。在6个月和12个月时,临床驱动的目标病变血运重建率分别为15%(25/172)和26%(42/162)。根据双重成像,1年再狭窄率为38.2%。踝臂指数从基线时的0.59 +/- 0.21显着增加到12个月时的0.82 +/- 0.27(p <0.05)。平均卢瑟福等级从基线的3.0 +/- 0.9改善到1年的1.5 +/- 1.3(p <0.05)。结论:即使在有挑战性病变的情况下,Pathway PV System在动脉粥样硬化病变中的使用似乎也可以安全有效地改善狭窄程度。干预后的血管通畅似乎长达12个月,并且这些结果转化为临床益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号